US · Healthcare · Biotechnology
EPS came in at -0.80 against a street estimate of -0.80 — a beat of 0.0%.
Analysts rate Intellia Therapeutics Inc a buy (22 buy, 6 hold, 1 sell out of 29) with an average price target of $24.00.
CONFIDENT Intellia reported positive Phase III HAELO results for lonvo-z in HAE with 87% attack reduction and rolling BLA underway for 1H27 launch. nex-z MAGNITUDE trial advancing with HLA genotyping identifying C*05:01 carriers at higher transaminase risk, now being incorporated into protocols. Q2 2026 No regional breakdown provided. Analysts pressed on HLA findings' commercial and label implications, ATTR trial design resilience post-CARDIO-TTRansform, and BLA filing status. Management emphasized genotyping as risk-stratification tool (not trial slowdown), defended nex-z's superior TTR profile vs. eplontersen-specific failure, and deferred BLA timeline detail to acceptance announcement. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 10.35% |
| BlackRock Inc | 8.67% |
| State Street Corp | 4.94% |
| D. E. Shaw & Co LP | 4.60% |
| Vanguard Portfolio Management, LLC | 4.44% |
| Two Sigma Investments LLC | 3.74% |
| Vanguard Capital Management, LLC | 3.63% |
| Regeneron Pharmaceuticals Inc | 2.64% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 INTELLIA THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • FDA accepted Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) on | 2026-09-08 |
| Material agreement · Q3 2026 INTELLIA THERAPEUTICS, INC. — 8-K FILING SUMMARY HEADLINE NUMBERS • $400 million total credit facility secured from OrbiMed on September 4, 2026 • $ | 2026-09-04 |
| Quarterly report · Q2 2026 INTELLIA THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and marketable securities (total liquidity): $437.8 million as of June | 2026-08-06 |
| Results announced · Q3 2026 INTELLIA THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net cash position: $628.4 million as of June 30, 2026 (up from $605.1 mil | 2026-08-06 |
| Reg FD disclosure · Q2 2026 INTELLIA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Primary Endpoint: 87% reduction in mean monthly attacks (lonvo-z vs. placebo, p<0.0001) | 2026-06-15 |
| Quarterly report · Q1 2026 INTELLIA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Net Loss: $96.2 million (vs. $114.3 million in Q1 2025) – improvement | 2026-05-11 |
| Proxy statement · Q2 2026 INTELLIA THERAPEUTICS, INC. – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of three Class I directors (Muna Bhanji, Bri | 2026-04-30 |
| Annual report FY2025 INTELLIA THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Intellia Therapeutics, Inc. (NASDAQ: NTLA), a CRISPR gen | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 positive data; FDA BLA acceptance anticipated H2 2026; U.S. launch H1 2027 Intellia Therapeutics announced strong progress on two CRISPR gene-editing drug candidates. Their lead drug, lonvo-z for hereditary angioedema (HAE), showed impressive Phase 3 trial results: | 2026-08-06 |
| Phase 3 data expected mid-2026; BLA submission planned H2 2026; launch anticipated H1 2027 Intellia Therapeutics, a CRISPR gene-editing company, reported Q4 2025 results with mixed progress. The company has two lead programs: lonvo-z for hereditary angioedema (HAE) and nex-z for A | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Intellia Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.